Epidermal growth factor and serum activate distinct pathways to inhibit the BH3 only protein BAD in prostate carcinoma LNCaP cells.
A better understanding of pathways involved in survival of prostate cancer cells is the key to develop effective and target-selective therapies. Presence of serum or epidermal growth factor in the culture medium of LNCaP cells decreases apoptosis induced by the inhibition of phosphatidylinositol 3-kinase with LY294002. However, intracellular pathway(s) involved in this survival signaling are not well defined. Here, we investigated the mechanism(s) involved in serum or epidermal growth factor-mediated inhibition of LY294002-induced death in LNCaP cells. Cell death was assessed by the percentage of cells in sub-G1 phase and caspase 3 activity. Phosphorylation status of BAD, ERK1/2 and RSKs were assessed by Western blot. Specific gene expression knock down of BAD, BAX, RSK1 and RSK2 were performed using siRNA transfections. Our results demonstrate that cell death induced by LY294002 is mediated by translocation of BAD and BAX proteins from the cytosol to the mitochondria. Whereas, epidermal growth factor activates a MAPK/ERK/RSK1 module leading to inactivation of BAD via Ser(75) phosphorylation, the presence of serum, on the other hand, induces a nonconducive intracellular environment for mitochondrial translocation of dephosphorylated BAD. Taken together, these results indicate that phosphorylation of BAD or inhibition of its translocation to the mitochondria are critical phosphatidylinositol 3-kinase-independent survival pathways in LNCaP cells.
Chao
O S P
OS
Department of Biochemistry, Faculty of Medicine, National University of Singapore, Singapore.
Clément
M-V
MV
D002277:Carcinoma / Q000097:blood / Q000378:metabolism*; D045744:Cell Line, Tumor; D004815:Epidermal Growth Factor / Q000502:physiology*; D006801:Humans; D008297:Male; D008928:Mitochondria / Q000378:metabolism; D010766:Phosphorylation; D011471:Prostatic Neoplasms / Q000097:blood / Q000378:metabolism*; D021381:Protein Transport / Q000502:physiology; D044967:Serum / Q000502:physiology*; D015398:Signal Transduction / Q000502:physiology*; D051025:bcl-Associated Death Protein / Q000037:antagonists & inhibitors* / Q000378:metabolism
C494819:BAD protein, human; D051025:bcl-Associated Death Protein; D004815:Epidermal Growth Factor